The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants

U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants

July 6, 2016 • By Jessica Dye

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—A U.S. judge has slashed a $500 million verdict against Johnson and Johnson and its DePuy unit over allegedly defective metal-on-metal Pinnacle hip implants to approximately $151 million.

You Might Also Like
  • Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants
  • Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

On Tuesday, U.S. District Judge Ed Kinkeade in the Northern District of Texas says he was compelled to reduce the verdict under a Texas state law limiting punitive damages according to a specific formula.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In March, the five plaintiffs and three of their spouses had been collectively awarded roughly $360 million in punitive damages, along with $140 million in compensatory damages, following a two-month trial.

Kinkeade also denied Johnson and Johnson’s bid to set aside the verdicts and order a new trial. The company argued that jurors were biased after hearing irrelevant and unfair evidence during trial. Plaintiffs’ lawyers had claimed the company was seeking an improper do-over after its trial strategy backfired.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Mark Lanier and Richard Arsenault, lead lawyers for the Pinnacle plaintiffs, says they disagreed with Texas’ cap on punitive damages but were pleased Johnson and Johnson’s bid for a new trial had been rejected.

A lawyer for Johnson and Johnson, John Beisner, says that the company is “confident that the trial verdict will be reversed on appeal.”

Johnson and Johnson and DePuy are facing roughly 8,400 lawsuits over the devices, which plaintiffs say contain design flaws that cause them to fail. The lawsuits claim friction between the devices’ metal components can shed ions into the bloodstream, leading to injuries, such as tissue death, bone erosion and high levels of metal in their blood.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Johnson and Johnson and DePuy have denied any wrongdoing in connection with developing and marketing the devices. DePuy stopped selling the metal-on-metal version of Pinnacle hips in 2013. That year, it paid $2.5 billion to settle more than 7,000 lawsuits over another metal-on-metal hip device, the ASR, which was recalled in 2010.

The $500 million verdict in March was the second in a trial involving Pinnacle hip devices. Johnson and Johnson was cleared of liability in the first trial, which involved a single plaintiff and ended in 2014. A third trial involving multiple plaintiffs is scheduled for September.

Filed Under: Drug Updates, Safety Tagged With: hip, hip replacement, implant, Johnson & Johnson, Legal

You Might Also Like:
  • Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants
  • Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs
  • Zimmer Wins First U.S. Trial over NexGen Flex Knee Devices

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.